FDA ‘yes’ for Eli Lilly’s Reyvow
The approval marks the first new class of acute migraine treatment approved by the FDA in more than two decades.
Read More
Tag: Reyvow
- MHRA approves new treatment for severe alopecia areata
- Aplagon doses first patient in phase 2a trial of APAC
- NHS to offer fezolinetant for menopause‑related hot flushes and night‑sweats
- UCB reports superiority of bimekizumab in psoriatic arthritis study
- Kainova reports positive results for DT‑9081 in advanced solid tumours
